24/7 Market News Snapshot 12 May, 2025 – CytomX Therapeutics, Inc. (NASDAQ:CTMX)

May 12, 2025

DENVER, Colo., 12 May, 2025 (www.247marketnews.com) – (NASDAQ:CTMX) are discussed in this article.
CytomX Therapeutics, Inc. is currently witnessing a decline in its stock performance, with a pre-market trading value of $0.909, marking a drop of approximately 2.09% from the previous close of $0.928. The trading volume reached a significant 1.69 million shares, suggesting a cautious sentiment among investors. This downward trend may result from recent market fluctuations or company-specific developments, with technical indicators such as moving averages hinting at potential support or resistance levels. Investors are advised to closely monitor these trends for informed decision-making.

Amid these market challenges, CytomX is making notable strides in its clinical developments, particularly with CX-2051, an innovative EpCAM antibody-drug conjugate designed to meet the urgent needs of advanced colorectal cancer patients. The company has shared promising interim findings from its ongoing Phase 1 dose escalation trial, prompting the initiation of dose expansions at doses of 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg. This progression underscores CX-2051 as CytomX’s primary focus, with plans to commence a Phase 2 study in advanced colorectal cancer projected for the first half of 2026.

Sean McCarthy, D.Phil., CEO and Chairman of CytomX, expressed optimism regarding the interim results, highlighting the team’s dedication to advancing treatments for patients with significant medical needs. Additionally, the company is advancing its Phase 1 study of CX-801, a PROBODY® interferon alpha-2b, with initial data from advanced melanoma expected in late 2025. CytomX also achieved significant progress in its research collaborations, including a $5 million milestone payment from Astellas.

As of the end of the first quarter of 2025, CytomX boasted $79.9 million in cash and equivalents, showcasing strong financial stability that supports its strategic emphasis on clinical advancements and cost management, extending its financial runway into mid-2026.

Related news for (CTMX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.